Search by Drug Name or NDC
NDC 59651-0450-60 Lifitegrast 50 mg/mL Details
Lifitegrast 50 mg/mL
Lifitegrast is a OPHTHALMIC FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Aurobindo Pharma Limited. The primary component is LIFITEGRAST.
MedlinePlus Drug Summary
Ophthalmic lifitegrast is used to treat the signs and symptoms of dry eye disease. Lifitegrast is in a class of medications called lymphocyte function-associated antigen-1 (LFA-1) antagonist. Lifitegrast works by reducing the swelling in the eye tissues.
Related Packages: 59651-0450-60Last Updated: 04/28/2024
MedLinePlus Full Drug Details: Lifitegrast Ophthalmic
Product Information
| NDC | 59651-0450 |
|---|---|
| Product ID | 59651-450_1d4b4b61-79da-4b6f-bb19-056d111bf400 |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | Lifitegrast |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Lifitegrast |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | FOR SOLUTION |
| Route | OPHTHALMIC |
| Active Ingredient Strength | 50 |
| Active Ingredient Units | mg/mL |
| Substance Name | LIFITEGRAST |
| Labeler Name | Aurobindo Pharma Limited |
| Pharmaceutical Class | Lymphocyte Function-Associated Antigen-1 Antagonist [EPC], Lymphocyte Function-Associated Antigen-1 Antagonists [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA215063 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 59651-0450-60 (59651045060)
| NDC Package Code | 59651-450-60 |
|---|---|
| Billing NDC | 59651045060 |
| Package | 60 POUCH in 1 CARTON (59651-450-60) / 5 AMPULE in 1 POUCH (59651-450-05) / .2 mL in 1 AMPULE |
| Marketing Start Date | 2023-11-07 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |